Therapy-related acute myeloid leukemia and its prevention. 2020

Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
Department of Chemical Carcinogenesis, Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation Moscow 115478, Russia.

BACKGROUND Secondary tumors, including therapy-related acute myeloid leukemia (t-AML), represent one of the most undesirable side effects of chemotherapy, which arise several years after primary cancer treatment. This review aims to analyze the current data on molecular pathogenesis of t-AML revealing potential criteria for predicting predisposition to the disease. Another objective is to analyze the information on promising approaches for t-AML prevention. METHODS We analyzed studies regarding t-AML and possible approaches for cancer prevention of drug-induced tumors. Publications in the databases, such as SciVerse Scopus (948), PubMed (1837) and Web of Science (935) were used. Among 92 the most important publications cited in the review, 79 were published during the last decade. RESULTS The review provides the information concerning t-AML pathogenesis, molecular markers of primary cancer patients with high risk of t-AML. The role of the bone marrow niche in clonal hematopoiesis and t-AML pathogenesis is discussed. Current approaches for t-AML prevention both at the stage of therapy and at the latent period are described. Inhibition effects of polyphenols on cell proliferation and on the appearance of hemopoetic clones of indeterminate potential are proposed for t-AML prevention. CONCLUSIONS The problem of the t-AML, a cancer induced by genotoxic chemotherapeutic drugs, is considered from the point of view of the fundamental mechanisms of chemical carcinogenesis, highlighting initiation and promotion stages. It enables to reveal the possible markers for the group of patients with high risk for t-AML and to demonstrate perspectives for the use of plant polyphenols for t-AML prevention.

UI MeSH Term Description Entries

Related Publications

Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
December 2013, Seminars in oncology,
Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
January 2015, Medical oncology (Northwood, London, England),
Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
January 2021, Journal of the Association of Genetic Technologists,
Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
March 2022, Critical reviews in oncology/hematology,
Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
February 2008, Leukemia,
Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
February 2023, International journal of hematologic oncology,
Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
January 2013, Acta haematologica,
Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
June 2022, Oncology letters,
Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
March 2020, Clinical lymphoma, myeloma & leukemia,
Gennady Belitsky, and Timur Fetisov, and Kirill Kirsanov, and Ekaterina Lesovaya, and Olga Vlasova, and Marianna Yakubovskaya
April 2023, Haematologica,
Copied contents to your clipboard!